Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus

Study of the Immune Response to SARS-CoV-2 Vaccination in Patients With Systemic Lupus

The main objective is to study the impact of vaccination against Covid-19 on the specific humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the pathological immune system of the disease), in a lupus population.

The secondary objective is to study the impact of lupus disease activity on the humoral and cellular response of patients following vaccination against SARS-CoV-2.

The hypothesis is that disease activity and / or certain treatments used in lupus may interfere with the humoral and cellular immune response induced by vaccination against SARS-CoV-2.

Inclusion Criteria:

• Adult subject (≥ 18 years old), male or female
• Patient with systemic lupus according to ACR 1997 criteria
• Patient followed by the National Reference Center "Rare Systemic Autoimmune Diseases" of the University Hospitals of Strasbourg
• Patient who agreed to be vaccinated against SARS-CoV-2
• Subject having expressed his non-opposition to the research
• Subject affiliated to a social health insurance protection scheme

Exclusion Criteria:

• Patient treated by:

  • Corticosteroids (> = 10mg / day)
  • Immunosuppressant (azathioprine, mycophenolate mofetil, cyclophosphamide) to control lupus activity
  • A biomedicine targeting B cells (rituximab, belumimab).

• Inability to provide informed information about the subject (subject in an emergency, difficulty in understanding the subject, etc.)

• Subject under safeguard of justice

• Subject under guardianship